Ponesimod more OPTIMUM than teriflunomide in relapsing MS
08 Apr 2021
byNatalia Reoutova
The phase III OPTIMUM (Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis) study shows that ponesimod is superior to teriflunomide in reducing annualized relapse rate (ARR), fatigue, MRI activity, and brain volume loss in relapsing multiple sclerosis (RMS).